Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON33697
NL-OMON33697
Not yet recruiting
Phase 4

The magnitude of platelet inhibition and the pharmacokinetics of a 600 mg loading dose of clopidogrel, in different patient categories (stable angina versus acute-coronary syndromes versus ST-elevated myocardial infarction). - The MAPCAT-study

Cardiology0 sites200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionspatients with a history of a stent thrombosis1003553410011082

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
patients with a history of a stent thrombosis
Sponsor
Cardiology
Enrollment
200
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Cardiology

Eligibility Criteria

Inclusion Criteria

  • •Group 1: Patients with a history of a stent thrombosis in the period 2002\-2009\.
  • •Group 2: Patients with ACS or stable AP.

Exclusion Criteria

  • •Persistent acute ST\-segment elevation
  • •Successful revascularization during the qualifying hospitalization, prior to study entry
  • •Acute pulmonary edema, hypotension, or evidence of cardiogenic shock
  • •Clinically significant liver disease
  • •End stage kidney disease requiring dialysis
  • •Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4 and CYP3A5 (i.e. clarithromycin, erythromycin, itraconazole, ketoconazole)
  • •Contraindications to antithrombotic/antiplatelet therapy
  • •Failed coronary intervention in the previous 2 weeks
  • •Malignancies
  • •Increased risk of bleeding (previous stroke in the past months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic dissection, oral anticoagulation therapy with coumarin derivate within 7 days, recent use of GPIIb/IIIa inhibitors within 14 days, severe uncontrolled hypertension \>180 mmHg unresponsive to therapy)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrelIschemic heart diseases with PIC
JPRN-UMIN000014161Kazuo Umemura Center for clinical research Hamamatsu University Hospital50
Not yet recruiting
Phase 3
To compare platelet inhibition with crushed versus whole tablet administration of clopidogrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous intervention procedure.Health Condition 1: I22- Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
CTRI/2020/06/025647Fluid Research Fund
Completed
Phase 4
ASsesment of Platelet function and Inhibition in patients Recovering from severe INfectionAcute myocardial infarctionHeart attack10011082
NL-OMON50157Vrije Universiteit Medisch Centrum97
Active, not recruiting
Phase 1
Evaluation of platelet activity in patients recovering from a severe infectioHyperaggregability of thrombocytes triggered by severe infection (i.e. pneumonia or invasive urinary tract infection or a cutaneous infection).Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-004303-32-NLVU university medical center62
Completed
Not Applicable
Platelet inhibiting drugs in eyelid surgery.Eyelid surgery, Platelet inhibitors, Haemorrhagic complications.Trefwoorden NL: Ooglidchirurgie, Plaatjesaggregatieremmers, Haemorrhagische complicaties.
NL-OMON29088Rotterdam Ophthalmic Institute, Het Oogziekenhuis Rotterdam324